

AMENDMENTS TO THE CLAIMS

1-7(withdrawn)

8 (currently amended) A pharmaceutical composition comprising a protein useful for treating a lysosomal storage disorder other than Fabry disease that is selectively imported into macrophages when administered to a subject and a pharmaceutically acceptable carrier, wherein said protein is produced in an insect cell culture and is selected from the group consisting of acid α -1,4 glucosidase, acid α -1,6 glucosidase, β -galactosidase, β -hexosaminidase A, GM₂ Activator Protein, β -hexosaminidase A, β -hexosaminidase B, glucocerebrosidase, β -glucosidase, galactosylcerebrosidase, acid sphingomyelinase, acid ceramidase, acid lipase, α -L-iduronidase, iduronate sulfatase, α -N-acetylglucosaminidase, acetyl-CoA-glucosaminide acetyltransferase, N-acetylglucosamine-6-sulfatase, galactosamine-6-sulfatase, arylsulfatase B, β -glucuronidase, arylsulfatase A, arylsulfatase C, α -Neuraminidase, UDP GlcNAc:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase, neuraminidase, α -mannosidase, β -mannosidase, α -L-fucosidase, N-aspartyl- β -glucosaminidase, protective protein/cathepsin A (PPCA), α -N-acetyl-galactosaminidase, cystine transport protein, sialic acid transport protein, palmitoyl-protein thioesterase, and Saposins A-D.

9 (Previously presented) The composition of claim 8 wherein said lysosomal storage disorder is Galactosialidosis.

10 (Previously presented) The composition of claim 8 wherein said protein is protective protein/cathepsin A (PPCA).

11 (original) The composition of claim 8 wherein said insect cell culture comprises cells derived from the species selected from the group consisting of *Spodoptera frugiperda* and *Tricoplusia ni*.

12 (original) The composition of claim 11 wherein said cells are *Spodoptera frugiperda* Sf9 cells.

13 (original) The composition of claim 8 wherein said protein is produced in the cell culture using a baculovirus expression system.

14-20 (withdrawn).